WASHINGTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- EB5 Capital today announced that U.S. Citizenship and Immigration Services (USCIS) has approved the I-956F petition for JF49 - Horseshoe Bay Senior Living, just under five months after filing. The approval marks EB5 Capital’s 20th I-956F approval since the enactment of the EB-5 Reform and Integrity Act of 2022 (RIA). With the Project approved, USCIS can now review each investor’s individual petition (Form I-526E), the next step toward permanent residency in the United States.
JF49 is EB5 Capital’s second senior living development and its first project in Texas. Located in a rural targeted employment area (TEA) in Horseshoe Bay, near Austin, the Class-A, four-story community sits adjacent to Horseshoe Bay Resort. Construction began in Q2 2026 and remains on schedule, with completion expected in Q2 2029. The community will include 180 units across three levels of care: 114 independent living units, 48 assisted living units, and 18 memory care units. Residents will have access to a range of amenities designed to support comfort, wellness, and connection at every stage of care.
JF49 also reflects the international reach of the EB-5 program. The Project’s investors were born in 13 countries, with the largest groups from India, Canada, and China, and range in age from 18 to 71. Their backgrounds span business ownership, technology, medicine, and higher education.
“Behind every petition is a family planning their future, and an approval in under five months is a testament to their careful Regional Center and project choice,” said Natalia Pronina, Vice President of Investor Relations at EB5 Capital. “JF49 brought together investors from around the world, including our first investor from Hungary, making it the 81st country represented in our investor community. Seeing families from so many places join this project reminds us why so many see the EB-5 Program as part of their family’s long-term plans, and why we are proud to support our investors through every step.”
EB5 Capital raised $48 million from 60 investors to support the Project’s $109.1 million total cost. JF49 is projected to create more than 770 jobs, exceeding the USCIS requirement of 600.
EB5 Capital extends its thanks to its sponsor, Falcon Senior Housing; operating partner, SilverPoint Senior Living; immigration counsel; and its own team for their collaboration on the I-956F petition. As construction continues, EB5 Capital looks forward to the Project’s completion and to the adjudication of each investor’s I-526E petition.
About EB5 Capital
EB5 Capital provides qualified foreign investors with opportunities to invest in job-creating commercial real estate projects under the United States Immigrant Investor Program (EB-5 Visa Program). Headquartered in Washington, D.C., EB5 Capital’s distinguished track record and leadership in the industry has attracted investors from 81 countries. As one of the oldest and most active Regional Center operators in the country, the firm has raised nearly $2 billion of foreign capital across 50 EB-5 projects. 100% of our investors’ funds are protected by the Federal Deposit Insurance Corporation (FDIC) insurance prior to their deployment into our projects. Please visit www.eb5capital.com for more information.
Contact:
Kyra Barackman
Manager, Marketing & Creative Design
marcomm@eb5capital.com
-
默沙东两款重磅罕见病创新药物欣瑞来®(注射用索特西普)和维利瑞®(贝组替凡片)纳入2026国家医保药品目录截至目前默沙东共有22款产品被纳入国家医保药品目录 上海2026年11月14日 美通社 -- 默沙东(默沙东是美国新泽西州罗威市默克公司的公司商号)宣布,全球首个且目前唯一2026-11-14
-
诺华产品盐酸阿曲生坦片成功纳入2026年国家医保药品目录上海2026年11月14日 美通社 -- 2026年11月14日,《国家基本医疗保险、生育保险和工伤保险药品目录(2026年)》(以下简称新版药品目录)以及《商业健康保险创新药品目录(20262026-11-14
-
全球首个 pMN 适应症创新药纳入医保,倍捷欣(奥妥珠单抗β)双适应症惠及膜性肾病与NMOSD患者北京2026年11月14日 美通社 -- 11月14日,国家医疗保障局、人力资源社会保障部印发《国家基本医疗保险、工伤保险和生育保险药品目录(2026年)》(以下简称新版医保目录),北2026-11-14
-
国产1类抗流感创新药济可舒纳入国家医保药品目录南京2026年11月14日 美通社 -- 近日,国家医保局公布《国家基本医疗保险、生育保险和工伤保险药品目录(2026年)》,征祥医药自主研发的1类抗流感创新药玛硒洛沙韦片(商品2026-11-14
-
科济药业恺力美®纳入《商业健康保险创新药品目录(2026年)》上海2026年11月14日 美通社 -- 科济药业(股票代码:2171.HK),一家专注于开发创新CAR-T细胞疗法的生物制药公司宣布,恺力美® (舒瑞基奥仑赛注射液,产品编号:CT041,一种靶向Clau2026-11-14
-
AMD股价暴跌17%创近9年之最,苏姿丰紧急回应:AI增速远超想象
-
锚定健康中国新征程!第一届医药信息传播论坛将于广州启幕
-
Ledger 中国销售渠道说明:广州馨潇贸易有限公司官方直营渠道公示
-
江苏省脑机接口产业联盟在宁成立,麦澜德分享前沿成果
-
艾芬达入选国家知识产权强国建设示范创建对象:二十载长期主义,兑现每一份用户价值
-
Esentia宣布成功完成2033年到期的6.125%优先票据和2038年到期的6.500%优先票据的定价
-
中荷人寿北京分公司成功举办中荷创享家品牌发布暨协同发展启航仪式
-
华为系具身智能公司具脑磐石完成新一轮融资:对标JEPA,押注类脑智能的认知世界模型
-
北京暑假补习班有哪些?家长首推一对一权威机构金博升学
-
上海高新技术企业代理机构深度访谈与推荐
